Trial Profile
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Olanzapine/samidorphan (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Alkermes plc
- 26 Jul 2018 Status changed from recruiting to completed.
- 19 Jul 2018 This trial was completed in Bulgaria, according to European Clinical Trials Database.
- 04 May 2017 This trial was completed in Slovakia, according to European Clinical Trials Database.